about
Concomitant Benznidazole and Suramin Chemotherapy in Mice Infected with a Virulent Strain of Trypanosoma cruziCurcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.Nonsteroidal anti-inflammatory is more effective than anti-oxidant therapy in counteracting oxidative/nitrosative stress and heart disease in T. cruzi-infected mice.Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.Euterpe edulis Extract but Not Oil Enhances Antioxidant Defenses and Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Rats.The energy density of laser light differentially modulates the skin morphological reorganization in a murine model of healing by secondary intention.Modulation of oxidative and inflammatory cardiac response by nonselective 1- and 2-cyclooxygenase inhibitor and benznidazole in mice.Depletion of enteroendocrine and mucus-secreting cells is associated with colorectal carcinogenesis severity and impaired intestinal motility in rats.Cadmium-induced testicular damage is associated with mineral imbalance, increased antioxidant enzymes activity and protein oxidation in rats.Acute paraquat exposure determines dose-dependent oxidative injury of multiple organs and metabolic dysfunction in rats: impact on exercise tolerance.Purinergic Antagonist Suramin Aggravates Myocarditis and Increases Mortality by Enhancing Parasitism, Inflammation, and Reactive Tissue Damage in -Infected MiceAccuracy of plasma interleukin-18 and adiponectin concentrations in predicting metabolic syndrome and cardiometabolic disease risk in middle-age Brazilian menAluminum: A potentially toxic metal with dose-dependent effects on cardiac bioaccumulation, mineral distribution, DNA oxidation and microstructural remodeling
P50
Q36075925-488812DB-BA32-40CB-96DA-BF1CBABE3616Q36933422-964AB053-1163-40BB-AFC6-E094825945EFQ40353829-25633FB0-26D0-4F78-BB5E-3B2B515A25B6Q41286010-21A164B5-7884-4FE7-B45B-B1571E9734B4Q42056613-D77B117F-3E11-479F-9392-081D23BAB665Q44685152-269D9E64-754C-49B2-8531-667A1C7A2947Q46710618-28465915-F172-4B56-AB2B-8466318E573DQ51001933-325C027A-D5FA-40DB-9352-B49D783EFEBDQ51097315-00FECEFD-8944-4E55-BAD6-8D1B1F3A05ADQ51713387-B36A334F-6F5E-491A-B9B7-D68D415FF43AQ58604358-74560365-2D4B-4736-B347-E128B23AF710Q61436579-882B6674-6476-421D-A143-39D818526CE7Q90386269-C04464A7-A6B7-484D-827D-590E7FE3A69D
P50
description
researcher (ORCID 0000-0003-0825-5836)
@en
name
Eliziaria C Santos
@en
type
label
Eliziaria C Santos
@en
prefLabel
Eliziaria C Santos
@en
P108
P31
P496
0000-0003-0825-5836